Meta-analysis on Cerebral Embolic Protection in TAVR

Meta-analysis on Cerebral Embolic Protection in TAVRCerebral embolic protection is a strategy to prevent embolization of thrombotic or calcific debris during transcatheter aortic valve replacement (TAVR). A number of randomized and controlled studies have tested the safety and efficacy of various devices, though none of them have enough statistical power to show significant differences in end points.  

 

While preliminary evidence suggests these devices may reduce cerebral infarction markers or improve post procedural cognitive function, their effect on hard clinical events remains unknown.

 

This is a meta-analysis of randomized studies evaluating cerebral embolic protection devices. Primary end point was death risk or stroke, according to the intention-to-treat principle.

 

It included a total of 5 randomized studies with 625 patients; 376 receiving some kind of cerebral embolic protection device and 249 control patients receiving no protection device.

 

Cerebral embolic protection devices showed lower death risk and stroke compared to the control group (6.4% vs. 10.8%; RR: 0.57; CI 95%: 0.33 to 0.98; p=0.04). The number needed to treat to avoid death or stroke was 22.

 

Outcomes were consistent when stratifying by device type, and magnitude and direction were also consistent with sequential exclusion of each of the studies (basically, no study or device tilted the scales).

 

When considering all cause death and stroke separately, there was a difference in favor of embolic protection devices, though not significant.

 

These findings suggest that cerebral embolic protection devices could be an adjunctive strategy in patients undergoing TAVR.

 

They seem to be particularly effective in patients at high risk of neurological events. However, for younger patients at lower risk, it is also important to prevent silent cerebral lesions, since they have been long associated to time related cognitive deterioration.

 

Conclusion

All data on cerebral embolic protection during transcatheter aortic valve replacement procedures (TAVR) appear to show they are associated to a significant lower risk of death or stroke.

 

Original Title: Cerebral Embolic Protection During TAVR. A Clinical Event Meta-Analysis.

Reference: Gennaro Giustino et al. J Am Coll Cardiol. 2017 Jan 31;69(4):465-466.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Prospective Analysis of the Feasibility of the PASCAL System for Transcatheter Mitral Repair: OneForAll Registry

Courtesy of Dr. Juan Manuel Pérez. Mitral transcatheter edge-to-edge repair (M-TEER) is an effective option for patients with severe mitral regurgitation who are at high...

Left Bundle Branch Block after TAVR: What Is Its Impact?

Courtesy of Dr. Juan Manuel Pérez. Left bundle branch block (LBBB) is a common complication following transcatheter aortic valve replacement (TAVR), which can be either...

Multicenter Experience with 3D Intracardiac Echocardiography for Guiding Interventional Cardiac Procedures

Courtesy of Dr. Juan Manuel Pérez. Imaging techniques play a fundamental role in interventional cardiac procedures. Intracardiac echocardiography (ICE) appears as an alternative to transesophageal...

Pathology of Self-Expanding Transcatheter Aortic Bioprostheses and Hypoattenuated Leaflet Thickening

Courtesy of Dr. Juan Manuel Pérez. Despite the available long term followup data on of transcatheter aortic valve replacement (TAVR), bioprosthesis durability continues under debate....

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...